BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT®
Authors Patti F, Martínez Ginés ML, Norenberg C, Duarte Caron F
Received 17 January 2020
Accepted for publication 26 March 2020
Published 28 April 2020 Volume 2020:14 Pages 771—779
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Francesco Patti,1 María Luisa Martínez Ginés,2 Christiane Norenberg,3 Fernando Duarte Caron4
1Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia; Multiple Sclerosis Center, University of Catania, Catania, Italy; 2Department of Neurology, Hospital General Universitario Gregorio Marañon, Madrid, Spain; 3Bayer AG, Wuppertal, Germany; 4Bayer, Whippany, New Jersey, NY, USA
Correspondence: Francesco Patti
Multiple Sclerosis Center, University of Catania, Piazza Università, 2, Catania 95131, Italy
Purpose: Patients with multiple sclerosis (MS) would benefit from continued long-term treatment with disease-modifying therapies, and autoinjectors may help improve patients’ satisfaction with therapy, thereby increasing adherence rates. BETACONNECT® is an autoinjector for interferon beta-1b designed to improve the injection experience for patients. The BetaEval Global study assessed medication intake in patients using BETACONNECT to further investigate the value of this autoinjector.
Patients and Methods: The BetaEval Global study was a prospective, non-interventional cohort study across multiple European countries in patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) who were starting interferon beta-1b treatment. The decision to administer interferon beta-1b was made independently of the study. Patients were assessed at the initial visits and planned follow-up visits at Weeks 4, 12, and 24. The primary outcome variable was compliance with therapy based on the medication possession ratio (MPR). Injections were automatically recorded by the BETACONNECT device or, in some instances, self-reported by the patients. This allowed for a complete dataset that could be used in the calculation of the MPR.
Results: Four hundred ninety-eight patients were enrolled and completed 93.9%, 95.2%, and 95.4% of prescribed injections at Weeks 4, 12, and 24, respectively. Similarly, 76.4% (n=318), 76.6% (n=297), and 81.1% (n=284) of patients completed at least 80% of their prescribed injections. Median scores assessing patient satisfaction with the autoinjector were consistently high across the study.
Conclusion: Overall, the results from BetaEval Global demonstrated that in this cohort of patients with RRMS or CIS on interferon beta-1b, use of the BETACONNECT autoinjector was associated with high rates of compliance, adherence, and patient satisfaction.
Keywords: multiple sclerosis, interferon beta-1b, autoinjector, adherence, disease-modifying therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]